Talis Biomedical (NASDAQ:TLIS) Trading Down 4.3%

Talis Biomedical Co. (NASDAQ:TLISGet Free Report) shares dropped 4.3% during mid-day trading on Tuesday . The company traded as low as $7.13 and last traded at $7.20. Approximately 7,849 shares changed hands during mid-day trading, an increase of 9% from the average daily volume of 7,218 shares. The stock had previously closed at $7.52.

Talis Biomedical Stock Performance

The company has a 50-day simple moving average of $7.92 and a 200 day simple moving average of $6.83. The company has a market capitalization of $13.10 million, a P/E ratio of -0.17 and a beta of 1.69.

Talis Biomedical (NASDAQ:TLISGet Free Report) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($8.62) EPS for the quarter. The business had revenue of $0.14 million during the quarter. Talis Biomedical had a negative return on equity of 72.82% and a negative net margin of 3,436.98%.

Institutional Trading of Talis Biomedical

A number of large investors have recently bought and sold shares of the stock. Prelude Capital Management LLC grew its position in Talis Biomedical by 36.2% in the first quarter. Prelude Capital Management LLC now owns 256,395 shares of the company’s stock valued at $362,000 after acquiring an additional 68,126 shares during the period. Millennium Management LLC bought a new stake in Talis Biomedical in the second quarter valued at $164,000. Renaissance Technologies LLC grew its position in Talis Biomedical by 549.3% in the second quarter. Renaissance Technologies LLC now owns 107,765 shares of the company’s stock valued at $88,000 after acquiring an additional 91,167 shares during the period. BML Capital Management LLC bought a new stake in Talis Biomedical in the fourth quarter valued at $318,000. Finally, Citigroup Inc. bought a new stake in Talis Biomedical in the third quarter valued at $30,000.

About Talis Biomedical

(Get Free Report)

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B.

Further Reading

Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.